Diagnosis of Alcoholic Hepatitis
Alcoholic hepatitis (AH) is diagnosed clinically based on rapid-onset jaundice with elevated AST in patients with heavy alcohol use (>40g/day for women, >50-60g/day for men for >6 months with <60 days abstinence), serum bilirubin >3 mg/dL, AST >50 IU/mL with AST/ALT ratio >1.5, and transaminases <400 IU/mL, after excluding other causes of acute hepatitis. 1
Clinical Diagnostic Framework
The 2020 AASLD guidelines and 2016 NIAAA consensus statement categorize AH diagnosis into three tiers 2, 1:
1. Definite AH (Biopsy-Proven)
- Clinical diagnosis confirmed by liver biopsy showing alcoholic steatohepatitis (ASH)
- Histologic hallmarks include macrovesicular steatosis plus ≥1 of:
- Neutrophil infiltration
- Hepatocyte ballooning
- Mallory-Denk bodies
- Additional features: megamitochondria, satellitosis, cholestasis, "chicken-wire" fibrosis pattern
- Biopsy is required when diagnosis is uncertain or confounding factors exist
2. Probable AH (Clinical Diagnosis Without Confounders)
- Heavy alcohol use meeting threshold criteria
- Characteristic laboratory pattern (see below)
- Negative workup for alternative diagnoses:
- ANA <1:160, anti-smooth muscle antibody <1:80
- Negative viral hepatitis markers
- Imaging excludes biliary obstruction
- No recent drug-induced liver injury (DILI) within 30 days
- No sepsis, shock, or cocaine use within 7 days
- Biopsy not required - misdiagnosis rate <10% in this group 1
3. Possible AH (Clinical Diagnosis With Confounders)
- Meets clinical criteria but has potential confounding factors:
- Recent GI bleeding, hypotension, or cocaine use
- Possible DILI
- Uncertain alcohol history
- Atypical laboratory pattern
- Liver biopsy strongly recommended - 10-20% may have alternative diagnoses 1
Essential Diagnostic Criteria
Alcohol Use History
- Duration: Heavy drinking >6 months, typically >5 years
- Amount: >3 drinks (
40g) daily for women; >4 drinks (50-60g) daily for men - Recent use: <60 days abstinence before jaundice onset 1
Laboratory Pattern
- Bilirubin: Usually >3 mg/dL (>50 μmol/L)
- AST: >50 IU/mL
- AST/ALT ratio: >1.5 (ratios <1.5 seen in <2% of biopsy-proven cases)
- Transaminase ceiling: AST and ALT typically <400 IU/mL (distinguishes from DILI and ischemic hepatitis) 1
Clinical Presentation
- Rapid-onset jaundice
- Malaise and tender hepatomegaly
- Often accompanied by decompensation: ascites, encephalopathy, bacterial infection, variceal bleeding 1
Critical Diagnostic Pitfalls
The NIAAA criteria have modest diagnostic accuracy (72%) with low sensitivity (63%), particularly in moderate AH (MELD <20). 3, 4 Recent evidence shows:
- Clinical criteria are 92% accurate in severe AH (MELD >20) but only 67% accurate in moderate AH (MELD <20) 3
- Adding C-reactive protein and refining NIAAA criteria (NIAAAm-CRP) improves sensitivity from 63% to 70% and accuracy from 72% to 78% 4
- Patients who don't meet NIAAA criteria but have ASH on biopsy have significantly worse 1-year survival (70% vs 90%) 4
When Liver Biopsy Is Required
Biopsy is mandatory for:
- Possible AH with confounding factors 2, 1
- Asymptomatic patients with elevated liver enzymes and suspected AH 5
- Atypical presentations where clinical diagnosis is uncertain 5
Biopsy is NOT required for:
Important caveat: 10-20% of clinically diagnosed AH cases have alternative diagnoses on biopsy, and liver biopsy has prognostic value beyond diagnosis 1. However, biopsy has limitations including sampling variability, lack of standardized grading systems, and procedural risks 1.
Severity Assessment After Diagnosis
Once diagnosed, use validated prognostic scores to assess severity and guide treatment:
- Maddrey Discriminant Function (MDF) ≥32: Identifies severe AH with 30-50% 28-day mortality risk
- MELD score: Extensively validated, though threshold for treatment initiation less defined
- Lille score at day 4-7: Determines corticosteroid response (>0.45 indicates non-response) 2
The combination of MELD plus Lille scores provides superior prognostic accuracy compared to either alone 2.